Showing 841-850 of 1116 results for "".
- 1-800 Contacts Announces New Company Focused on B2B Vision Technologies and Serviceshttps://modernod.com/news/1-800-contacts-announces-new-company-focused-on-b2b-vision-technologies-and-services/2480662/1-800 Contacts recently announced the formation of a standalone business, Luna Solutions, focused on providing technology and services to third parties in the vision space. The company offers 20 integrated technologies and services–ranging from telehealth platforms for n
- Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meetinghttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from N
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- CooperVision Presents Presbyopia Research, Introduces MyDay Daily Disposable Multifocal at Academy 2021https://modernod.com/news/coopervision-presents-presbyopia-research-introduces-myday-daily-disposable-multifocal-at-academy-2021/2480390/As part of the American Academy of Optometry 2021 virtual press conference, CooperVision presented results of research into the daily complexity of dealing with presbyopia and how this may affect clinical choices. The work was conducted in support of the launch of CooperVision’s new MyDay&n
- Oyster Point Pharma Receives FDA Approval of Tyrvaya Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-receives-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2480356/Oyster Point Pharma announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. The approval marks the first and only nasal spray approved for the treatment of dry eye disease. Tyrvaya&n
- Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-cohort-1-of-oasis-phase-1-2a-trial-of-cls-ax-for-the-treatment-of-wet-amd/2479292/Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in six patients (n=6) with neovascular age-rel
- Pfizer CEO Predicts Third COVID-19 Vaccine Booster “Likely” Needed Within Yearhttps://modernod.com/news/pfizer-ceo-predicts-third-covid-19-vaccine-booster-likely-needed-within-year/2479086/Pfizer CEO Albert Bourla believes it will probably be necessary for people to receive yet another dose of COVID-19 vaccine within a year of being fully vaccinated in order to stave off infection, according to recent taped comments that were made public on Thursday. “There will be likely a n
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N
- American Academy of Optometry Foundation Announces the 2020 Alfred A. Rosenbloom Jr. Low Vision Residency Award Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-alfred-a-rosenbloom-jr-low-vision-residency-award-recipient/2478194/The American Academy of Optometry has announced that Carolyn N. Chakuroff, OD, MS, is this year’s recipient of the Alfred A. Rosenbloom Jr. Low Vision Residency Award. Dr. Chakuroff is a graduate of The Ohio State University College of Optometry and an Ocular Disease/Low Vision Rehabilitation res
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n